CFD'er er komplekse instrumenter, og der er stor risiko for at miste penge hurtigt på grund af gearing. 84% af individuelle investorer taber penge, når de handler CFD'er med denne udbyder. Du bør overveje, om du forstår, hvordan CFD'er virker, og om du har råd til at løbe en høj risiko for at miste dine penge.
Capital Com Australia Pty Ltd Reguleret af ASIC Capital Com UK Limited Reguleret af Financial Conduct Authority (FCA) Capital Com SV Investments Limited Reguleret af CYSEC Сlosed Joint Stock Company «FinTech Solutions» Reguleret af NBRB Smart Forex Broker LLC Capital Com Stock and CFD Investing Ltd Reguleret af FSA Capital Com Online Investments Ltd Reguleret af SCB Our Global Offices

Scan to Download iOS&Android APP

English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文
Du kan også kontakte os: ring +44 2030978888 support@capital.com

Handel FibroGen, Inc - FGEN CFD

19.31
3.37%
0.25
Lav: 18.85
Høj: 19.4
Market Trading Hours* (UTC) Opens on Thursday at 13:30

Mon - Fri: 13:30 - 20:00

  • Opsummering
  • Historisk Data
  • Begivenheder
  • Resultatopgørelse
  • Saldo
  • Cash flow
  • Ejerskab
Handelsbetingelser
Spænd 0.25
Long position, gebyr natten over

Long position overnight fee

Margin. Your investment $1,000.00
Gebyr for natten over -0.024068 %
Charges from borrowed part ($-0.96)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Gå til platform
-0.024068%
Short position, gebyr natten over

Short position overnight fee

Margin. Your investment $1,000.00
Gebyr for natten over 0.001846 %
Charges from borrowed part ($0.07)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Gå til platform
0.001846%
Gebyr natten over, tid 21:00 (UTC)
Min. handlet mængde 1
Valuta USD
Margen 20%
Aktiebørs United States of America
Kommission på handel 0%

*Information provided by Capital.com

Nøglestatistikker
Tidligere luk* 18.68
Åben* 18.85
1-Års Ændring* 53.25%
Dagens Spænd* 18.85 - 19.4
52-Ugers Spænd 7.81-25.69
Gennemsnitlig Volumen (10 dage) 843.20K
Gennemsnitlig Volumen (3 måneder) 19.49M
Market Cap 1.76B
P/E-forhold -100.00K
Udestående aktier 94.18M
Omsætning 140.74M
EPS -3.14
Dividend (Udbytte %) N/A
Beta 0.83
Næste indtjeningsopgørelse May 8, 2023

Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Luk Change Change (%) Åben High Low
Mar 29, 2023 19.31 0.49 2.60% 18.82 19.41 18.50
Mar 28, 2023 18.68 0.30 1.63% 18.38 18.92 18.17
Mar 27, 2023 18.57 0.64 3.57% 17.93 18.68 17.79
Mar 24, 2023 18.13 -0.11 -0.60% 18.24 18.44 17.91
Mar 23, 2023 18.59 0.17 0.92% 18.42 18.90 18.05
Mar 22, 2023 18.57 -0.47 -2.47% 19.04 19.31 17.96
Mar 21, 2023 19.35 -0.74 -3.68% 20.09 20.09 19.09
Mar 20, 2023 19.85 0.12 0.61% 19.73 19.98 19.64
Mar 17, 2023 19.87 0.37 1.90% 19.50 20.08 19.08
Mar 16, 2023 20.12 0.44 2.24% 19.68 20.56 19.43
Mar 15, 2023 19.91 0.60 3.11% 19.31 20.03 19.31
Mar 14, 2023 20.01 0.08 0.40% 19.93 20.67 19.80
Mar 13, 2023 19.99 0.47 2.41% 19.52 20.16 19.47
Mar 10, 2023 20.07 0.18 0.90% 19.89 20.18 19.44
Mar 9, 2023 20.04 -0.99 -4.71% 21.03 21.14 19.91
Mar 8, 2023 20.98 0.23 1.11% 20.75 21.23 20.64
Mar 7, 2023 21.29 -0.13 -0.61% 21.42 21.49 21.02
Mar 6, 2023 21.61 -0.03 -0.14% 21.64 21.72 21.22
Mar 3, 2023 21.98 0.76 3.58% 21.22 22.05 21.22
Mar 2, 2023 22.12 0.96 4.54% 21.16 22.40 20.81

FibroGen, Inc Events

Tid (UTC) (UTC) Land Begivenhed
No events scheduled
Se alle begivenheder
  • Årlig
  • Pr kvartal
2022 2021 2020 2019 2018
Total omsætning 140.734 235.309 176.319 256.577 212.958
Omsætning 140.734 235.309 176.319 256.577 212.958
Totale Driftsudgifter 441.759 523.839 368.199 345.891 299.651
Salgs/Generelle/Admin. Udgifter, Total 127.474 120.557 97.238 126.557 63.812
Forskning & Udvikling 296.791 387.043 252.924 209.265 235.839
Driftsindtægter -301.025 -288.53 -191.88 -89.314 -86.693
Renteindkomst (Udgift), Netto Ikke-Drift 6.156 -2.153 3.151 12.672 0.577
Netto Indkomst Før Skat -294.869 -290.683 -188.729 -76.642 -86.116
Netto Indkomst Efter Skat -295.227 -291.03 -189.089 -76.97 -86.42
Netto Indkomst Før Ekstra Ting -293.654 -290.023 -189.291 -76.97 -86.42
Netto Indkomst -293.654 -290.023 -189.291 -76.97 -86.42
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -293.654 -290.023 -189.291 -76.97 -86.42
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -293.654 -290.023 -189.291 -76.97 -86.42
Fortyndet Netto Indkomst -293.654 -290.023 -189.291 -76.97 -86.42
Fortyndet Vægtet Gennemsnit Aktier 93.582 92.349 89.854 86.633 84.062
Fortyndet EPS Uden Ekstraordinære Ting -3.13793 -3.14051 -2.10665 -0.88846 -1.02805
Fortyndet Normaliseret EPS -3.13793 -3.14051 -2.10665 -0.88846 -1.02805
Totale Ekstraordinære Ting
Kost af omsætning, Total 20.28 12.871 8.869 1.147
Bruttofortjeneste 120.454 222.438 167.45 255.43
Depreciation / Amortization 0.587 4.639 10.369 10.307
Other Operating Expenses, Total -3.373 -1.271 -1.201 -1.385
Equity In Affiliates 1.573 1.007 -0.202
Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
Total omsætning 34.367 15.735 29.806 60.827 16.543
Omsætning 34.367 15.735 29.806 60.827 16.543
Kost af omsætning, Total 4.925 4.308 6.809 4.238 3.125
Bruttofortjeneste 29.442 11.427 22.997 56.589 13.418
Totale Driftsudgifter 100.519 109.392 108.03 123.82 151.784
Salgs/Generelle/Admin. Udgifter, Total 33.966 29.902 30.258 30.564 35.172
Forskning & Udvikling 61.628 75.182 70.963 89.018 113.92
Other Operating Expenses, Total -0.433
Driftsindtægter -66.152 -93.657 -78.224 -62.993 -135.241
Renteindkomst (Udgift), Netto Ikke-Drift -0.195 1.714 5.058 -0.419 0.932
Netto Indkomst Før Skat -66.347 -91.943 -73.166 -63.412 -134.309
Netto Indkomst Efter Skat -66.455 -92.057 -73.189 -63.525 -134.421
Equity In Affiliates 0.28 0.407 0.565 0.32 0.343
Netto Indkomst Før Ekstra Ting -66.175 -91.65 -72.624 -63.205 -134.078
Netto Indkomst -66.175 -91.65 -72.624 -63.205 -134.078
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -66.175 -91.65 -72.624 -63.205 -134.078
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -66.175 -91.65 -72.624 -63.205 -134.078
Fortyndet Netto Indkomst -66.175 -91.65 -72.624 -63.205 -134.078
Fortyndet Vægtet Gennemsnit Aktier 94.035 93.767 93.475 93.043 92.778
Fortyndet EPS Uden Ekstraordinære Ting -0.70373 -0.97742 -0.77694 -0.67931 -1.44515
Dividends per Share - Common Stock Primary Issue 0 0 0
Fortyndet Normaliseret EPS -0.70373 -0.97742 -0.77694 -0.67931 -1.44515
  • Årlig
  • Pr kvartal
2021 2020 2019 2018 2017
Totale Nuværende Aktiver 474.059 755.11 702.49 690.015 748.97
Likvider og Kortsigtede Investeringer 405.19 686.537 533.757 621.402 735.718
Cash 111.422 88.046 40.715 38.783 103.716
Likvider & Lignende 59.801 590.347 85.551 50.475 569.942
Kortsigtede Investeringer 233.967 8.144 407.491 532.144 62.06
Totale Tilgodehavender, Netto 25.401 41.883 153.665 63.684 8.452
Accounts Receivable - Trade, Net 36.331 46.01 158.51 16.474 4.448
Prepaid Expenses 7.383 8.353 6.464 4.929 4.8
Total Assets 773.821 826.84 857.397 880.598 898.65
Property/Plant/Equipment, Total - Net 120.15 65.296 84.276 127.198 129.476
Property/Plant/Equipment, Total - Gross 252.362 199.305 195.752 192.397 189.117
Accumulated Depreciation, Total -132.212 -134.009 -111.476 -65.199 -59.641
Long Term Investments 171.621 2.972 61.118 55.82 10.506
Other Long Term Assets, Total 7.991 3.462 9.513 7.565 9.698
Total Current Liabilities 225.497 163.187 102.745 89.033 85.96
Accounts Payable 26.097 24.789 6.088 9.139 5.509
Accrued Expenses 180.356 104.384 83.816 66.123 63.781
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 19.033 21.684 0.49 13.771 16.67
Total Liabilities 564.675 404.662 341.262 371.399 370.183
Total Long Term Debt 17.616 44.088 55.531 113.955 115.007
Long Term Debt 17.613 18.697 16.78 16.798 17.244
Capital Lease Obligations 0.003 25.391 38.751 97.157 97.763
Minority Interest 19.967 19.271 19.271 19.271 19.271
Other Liabilities, Total 292.403 169.441 163.715 149.14 149.945
Total Equity 209.146 422.178 516.135 509.199 528.467
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.929 0.914 0.877 0.854 0.825
Additional Paid-In Capital 1476.41 1399.77 1300.72 1226.45 1160.09
Retained Earnings (Accumulated Deficit) -1264.03 -974.011 -784.72 -715.827 -630.657
Other Equity, Total -4.163 -4.499 -0.747 -2.281 -1.795
Total Liabilities & Shareholders’ Equity 773.821 826.84 857.397 880.598 898.65
Total Common Shares Outstanding 92.881 91.441 87.657 85.432 82.498
Total Inventory 31.015 16.53 6.887
Other Current Assets, Total 5.07 1.807 1.717
Current Port. of LT Debt/Capital Leases 0.011 12.33 12.351
Deferred Income Tax 9.192 8.675
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Totale Nuværende Aktiver 524.415 474.059 573.399 564.466 621.694
Likvider og Kortsigtede Investeringer 428.075 405.19 486.402 507.212 544.232
Cash 165.436 111.422 90.899 130.035 100.735
Likvider & Lignende 20.46 59.801 183.628 223.326 332.773
Kortsigtede Investeringer 242.179 233.967 211.875 153.851 110.724
Totale Tilgodehavender, Netto 43.883 25.401 43.994 24.266 44.573
Accounts Receivable - Trade, Net 82.638 36.331 67.12 37.618 77.42
Total Inventory 43.067 31.015 29.315 24.53 20.764
Prepaid Expenses 9.39 7.383 6.598 7.149 9.602
Other Current Assets, Total 5.07 7.09 1.309 2.523
Total Assets 745.934 773.821 850.513 808.618 787.301
Property/Plant/Equipment, Total - Net 114.871 120.15 123.878 128.622 63.32
Property/Plant/Equipment, Total - Gross 252.362 249.986 249.741 202.703
Accumulated Depreciation, Total -132.212 -126.108 -121.119 -139.383
Long Term Investments 97.643 171.621 146.057 108.841 96.162
Other Long Term Assets, Total 9.005 7.991 7.179 6.689 6.125
Total Current Liabilities 255.374 225.497 209.316 232.764 167.047
Accounts Payable 36.353 26.097 23.868 48.988 24.061
Accrued Expenses 211.518 180.356 151.842 153.263 103.802
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.011 0.015 0.023 12.48
Other Current Liabilities, Total 7.503 19.033 33.591 30.49 26.704
Total Liabilities 587.886 564.675 524.721 548.038 416.299
Total Long Term Debt 17.374 17.616 17.919 18.283 40.155
Long Term Debt 17.374 17.613 17.914 18.277 17.962
Capital Lease Obligations 0.003 0.005 0.006 22.193
Deferred Income Tax 9.192 9.12 8.985 9.025
Minority Interest 19.967 19.967 19.271 19.271 19.271
Other Liabilities, Total 295.171 292.403 269.095 268.735 180.801
Total Equity 158.048 209.146 325.792 260.58 371.002
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.933 0.929 0.927 0.926 0.921
Additional Paid-In Capital 1490.86 1476.41 1458.98 1443.97 1420.47
Retained Earnings (Accumulated Deficit) -1327.24 -1264.03 -1129.96 -1179.75 -1045.77
Other Equity, Total -6.505 -4.163 -4.158 -4.567 -4.624
Total Liabilities & Shareholders’ Equity 745.934 773.821 850.513 808.618 787.301
Total Common Shares Outstanding 93.289 92.881 92.708 92.609 92.08
  • Årlig
  • Pr kvartal
2021 2020 2019 2018 2017
Netto indkomst/Startlinje -290.023 -189.291 -76.97 -86.42 -120.875
Likvider Fra Driftsaktiviteter -82.232 81.602 -78.705 -76.144 -66.513
Likvider Fra Driftsaktiviteter 14.809 22.047 21.454 6.562 6.099
Ikke-Likvide Ting 132.899 74.216 62.47 52.112 39.245
Likvid Rente Betalt 0.094 0.135 0.174 0.218 0.255
Ændringer i Driftskapital 60.083 174.63 -85.659 -48.398 9.018
Likvider fra Investeringsaktiviteter -426.972 452.487 120.018 -522.123 69.866
Kapitaludgifter -30.186 -3.994 -5.762 -8.02 -8.5
Andre Investerings-Cash-Flow-Ting, Total -396.786 456.481 125.78 -514.103 78.366
Likvider fra Financieringsaktiviteter -0.563 13.343 -4.3 13.875 496.472
Financiering af Cash-Flow-Ting -7.372 -11.463 -12.75 -15.612 -9.24
Udstedelse (Pensionering) af Aktier, Netto 12.701 37.829 20.778 29.847 506.115
Udstedelse (Pensionering) af Gæld, Netto -5.892 -13.023 -12.328 -0.36 -0.403
Udenlandsk Børs Effekter 2.597 4.695 -0.005 -0.008 0.051
Netto Ændring i Likviditet -507.17 552.127 37.008 -584.4 499.876
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -63.205 -290.023 -155.945 -205.743 -71.755
Cash From Operating Activities -8.476 -82.232 -27.272 -71.527 -44.984
Cash From Operating Activities 2.584 14.809 12.226 9.635 5.339
Non-Cash Items 17.77 132.899 80.124 63.854 19.755
Changes in Working Capital 34.375 60.083 36.323 60.727 1.677
Cash From Investing Activities 25.935 -426.972 -376.405 -254.252 -196.719
Capital Expenditures -36.638 -30.186 -28.79 -2.215 -0.518
Other Investing Cash Flow Items, Total 62.573 -396.786 -347.615 -252.037 -196.201
Cash From Financing Activities -2.893 -0.563 -0.532 0.301 -2.08
Financing Cash Flow Items -2.974 -7.372 -6.734 -5.928 -4.757
Issuance (Retirement) of Stock, Net 0.183 12.701 11.863 11.756 6.077
Issuance (Retirement) of Debt, Net -0.102 -5.892 -5.661 -5.527 -3.4
Foreign Exchange Effects 0.107 2.597 0.343 0.446 -1.102
Net Change in Cash 14.673 -507.17 -403.866 -325.032 -244.885
Investornavn Investortype Procent udestående Aktiebeholdning Aktieændring Beholdningsdato IOmsætningsscore
PRIMECAP Management Company Investment Advisor 14.7533 13895078 715181 2022-12-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 10.0058 9423765 -296873 2022-12-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 6.4049 6032318 22573 2022-12-31 LOW
Astellas Pharma Inc Corporation 5.2752 4968367 0 2022-01-31 LOW
Point72 Asset Management, L.P. Hedge Fund 5.077 4781645 3945 2022-12-31 HIGH
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.5284 4264977 40527 2022-12-31 LOW
Armistice Capital LLC Hedge Fund 4.1027 3864000 -592000 2022-12-31 HIGH
First Trust Advisors L.P. Investment Advisor 3.1594 2975653 -650483 2022-12-31 LOW
Adage Capital Management, L.P. Hedge Fund 2.8137 2650000 -100000 2022-12-31 LOW
Schroder Investment Management North America Inc. Investment Advisor 1.8302 1723777 381778 2022-12-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.7594 1657095 52068 2022-12-31 LOW
Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 1.6004 1507315 3988 2022-12-31 MED
Baker Bros. Advisors LP Hedge Fund 1.4601 1375211 559493 2022-12-31 LOW
Two Sigma Investments, LP Hedge Fund 1.2874 1212474 129222 2022-12-31 HIGH
Riggs (Rory B) Individual Investor 1.0583 996763 0 2022-01-31 HIGH
Eagle Asset Management, Inc. Investment Advisor/Hedge Fund 0.9589 903132 164502 2022-12-31 LOW
T. Rowe Price Associates, Inc. Investment Advisor 0.9539 898445 898445 2022-12-31 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.8378 789106 146602 2022-12-31 LOW
AllianceBernstein L.P. Investment Advisor/Hedge Fund 0.8375 788738 147750 2022-12-31 LOW
Marshall Wace LLP Investment Advisor/Hedge Fund 0.8001 753546 -6441 2022-12-31 HIGH

Hvorfor vælge Capital.com? Vores tal taler for sig selv.

Capital.com Group

500K+

Handlende

92K+

Månedlkige, aktive klienter

$53M+

Månedlig investeringsvolumen

$30M+

Hævet hver måned

Handelslommeregner

Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).

Handelskurtage
0
  • 1:1
Gearing
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben

Luk

Short Long
Tidligere resultater er ikke en pålidelig indikator for fremtidige resultater
Fortjeneste/Tab

FibroGen, Inc Company profile

Om FibroGen, Inc

FibroGen, Inc. er en biofarmaceutisk virksomhed. Selskabet beskæftiger sig med at opdage, udvikle og markedsføre en pipeline af første klasses terapeutika. Virksomheden anvender sine kompetencer inden for hypoxi-inducerbar faktor (HIF) biologi, 2-oxoglutarat enzymologi og bindevævsvækstfaktor (CTGF) biologi til at udvikle lægemidler til behandling af anæmi, fibrotiske sygdomme og kræft. Selskabets produkt Roxadustat er en oral småmolekylær inhibitor af HIF-prolyl hydroxylase (HIF-PH)-aktivitet til behandling af anæmi forårsaget af kronisk nyresygdom (CKD). Virksomheden er også ved at udvikle Roxadustat til behandling af anæmi i forbindelse med myelodysplastiske syndromer (MDS). Virksomheden er også ved at udvikle Roxadustat til behandling af kemoterapi-induceret anæmi (CIA). Pamrevlumab, et anti-CTGF humant monoklonalt antistof til behandling af idiopatisk lungefibrose (IPF), lokalt fremskreden uoprettelig bugspytkirtelkræft (LAPC) og Duchennes muskeldystrofi (DMD).

Industry: Biotechnology & Medical Research (NEC)

409 Illinois Street
SAN FRANCISCO
CALIFORNIA 94158
US

Resultatopgørelse

  • Annual
  • Quarterly

Folk ser også

Oil - Crude

72.81 Price
-1.210% 1D Chg, %
Long position, gebyr natten over -0.0162%
Short position, gebyr natten over -0.0057%
Gebyr natten over, tid 21:00 (UTC)
Spænd 0.03

US100

12,819.30 Price
+1.480% 1D Chg, %
Long position, gebyr natten over -0.0241%
Short position, gebyr natten over 0.0018%
Gebyr natten over, tid 21:00 (UTC)
Spænd 1.8

BTC/USD

28,443.80 Price
+3.920% 1D Chg, %
Long position, gebyr natten over -0.0616%
Short position, gebyr natten over 0.0137%
Gebyr natten over, tid 21:00 (UTC)
Spænd 60.00

Gold

1,961.06 Price
-0.790% 1D Chg, %
Long position, gebyr natten over -0.0087%
Short position, gebyr natten over 0.0005%
Gebyr natten over, tid 21:00 (UTC)
Spænd 0.30

Leder du stadig efter en mægler, du kan stole på?

Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com

1. Opret og bekræft din konto 2. Lav en inddbetaling 3. Find din handel